The key is to improve the standard system for the export of traditional Chinese Medicine

Over the years, due to the "green barriers" in foreign countries, the export of traditional Chinese medicine has repeatedly hit a wall As a big country of traditional Chinese medicine, the export volume of traditional Chinese medicine only accounts for 3% - 5% of the world's traditional Chinese medicine market What's more worrying is that foreign pharmaceutical enterprises import herbal extracts from China, and after deep processing in foreign countries, they become "foreign herbal medicine" with high price for resale According to the statistics of China Chamber of Commerce for the import and export of medical and health products, in the first quarter of 2013, the export volume of plant extracts reached US $330 million, an increase of 11.2% year on year, accounting for 47% of the export volume of traditional Chinese medicine In recent years, the export volume of plant extracts in China has increased year by year, reaching US $820 million in 2010, exceeding US $1 billion in 2011, reaching US $1.16 billion in 2012, and the export volume of plant extracts has reached US $1.16 billion It is processed into "foreign traditional Chinese medicine" with higher added value, most of which are sold to China, the world's largest consumer of traditional Chinese medicine According to the media, Jiuxin Pill developed by Japanese Jiuxin Pharmaceutical Co., Ltd with traditional Chinese medicine Liushen Pill has achieved sales of hundreds of millions of dollars every year, and most of these sales are from China Germany imports a large number of cheap ginkgo leaves from China every year, and the products produced are resold back to China at a price 10 times higher than the original value According to incomplete statistics, "foreign traditional Chinese medicine" has accounted for one third of the domestic market of Chinese patent medicine Stimulated by the success of Japanese Jiuxin Pharmaceutical Co., Ltd in entering Chinese medicine, more and more multinational companies are seeking opportunities for R & D and investment in traditional Chinese medicine GlaxoSmithKline, which is currently involved in bribery, has previously publicly said that its R & D center in Shanghai will launch research and development of traditional Chinese medicine At the beginning of this year, Lijie, a giant in the UK's FMCG industry, announced its acquisition of Guilin pharmaceutical, a traditional Chinese medicine company Traditional Chinese medicine industry has always been a traditional advantage industry in China It has a long history of thousands of years and is the treasure of the Chinese nation For many years, traditional Chinese medicine (TCM) has occupied half of China's pharmaceutical industry with its advantages of large output, wide distribution and small side effects However, on the other hand, China's lack of attention to the traditional Chinese medicine industry, the technical standard system of the traditional Chinese medicine industry is not perfect, leading to the slow development of the traditional Chinese medicine industry, and the internationalization of traditional Chinese medicine is difficult.